Contera Pharma A/S
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Oct 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 17, 2027The maintenance fee for Combinations of serotonin receptor agonists for treatment of movement disorders (US 9,186,359) comes due May 17, 2027. Unpaid by Nov 17, 2027, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Orally available pharmaceutical formulation suitable for improved management of movement disorders (US 10,561,618) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 1 fee due Oct 28, 2027The maintenance fee for Combinations of serotonin receptor agonists for treatment of movement disorders (US 10,632,116) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Pulsatile Drug Delivery System for Treating Morning Akinesia (US 11,975,104) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,186,359 | Combinations of serotonin receptor agonists for treatment of movement disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 10,632,116 | Combinations of serotonin receptor agonists for treatment of movement disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 10,561,618 | Orally available pharmaceutical formulation suitable for improved management of movement disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 11,478,476 | Use of buspirone metabolites In force · From the USPTO record | In force | From the USPTO record | |
| US 11,975,104 | Pulsatile Drug Delivery System for Treating Morning Akinesia In force · High confidence | In force | High confidence | |
| US 12,773,389 | Pulsatile Drug Delivery System for Treating Morning Akinesia In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned · 2 no status recorded